Prostate Cancer Prevention

·
· Recent Results in Cancer Research āļŦāļ™āļąāļ‡āļŠāļ·āļ­āđ€āļĨāđˆāļĄāļ—āļĩāđˆ 202 · Springer Science & Business Media
eBook
169
āļŦāļ™āđ‰āļē
āļ„āļ°āđāļ™āļ™āđāļĨāļ°āļĢāļĩāļ§āļīāļ§āđ„āļĄāđˆāđ„āļ”āđ‰āļĢāļąāļšāļāļēāļĢāļ•āļĢāļ§āļˆāļŠāļ­āļšāļĒāļ·āļ™āļĒāļąāļ™ Â āļ”āļđāļ‚āđ‰āļ­āļĄāļđāļĨāđ€āļžāļīāđˆāļĄāđ€āļ•āļīāļĄ

āđ€āļāļĩāđˆāļĒāļ§āļāļąāļš eBook āđ€āļĨāđˆāļĄāļ™āļĩāđ‰

Prostate cancer is by far the most common cancer in men and the second leading cause of death due to cancer. It comprises a mixed group of tumours displaying varying clinical behaviour: while some have a very aggressive course, others are rather indolent. Prevention of prostate cancer and discrimination between aggressive and indolent forms are important clinical goals and the acquisition of significant new evidence on means of achieving these aims makes this book particularly timely. A wide range of topics are covered by leading authorities in the field. The biology and natural history of prostate cancer are reviewed and the role of lifestyle and dietary factors, assessed. Detailed attention is paid to risk prediction biomarkers and to the role of novel high-throughput nucleic acid-based technologies in improving risk prediction and thereby allowing tailored approaches to cancer prevention. Potential means of chemoprevention of prostate cancer are also reviewed in depth, covering the very positive new data on the impact of aspirin as well as evidence regarding 5Îą-reductase inhibitors, DFMO and lycopene. Guidance is provided on the differentiation of aggressive from indolent disease and the policy and research implications of recent findings are examined. This book will be of interest to both clinicians and researchers.

āđƒāļŦāđ‰āļ„āļ°āđāļ™āļ™ eBook āļ™āļĩāđ‰

āđāļŠāļ”āļ‡āļ„āļ§āļēāļĄāđ€āļŦāđ‡āļ™āļ‚āļ­āļ‡āļ„āļļāļ“āđƒāļŦāđ‰āđ€āļĢāļēāļĢāļąāļšāļĢāļđāđ‰

āļ‚āđ‰āļ­āļĄāļđāļĨāđƒāļ™āļāļēāļĢāļ­āđˆāļēāļ™

āļŠāļĄāļēāļĢāđŒāļ—āđ‚āļŸāļ™āđāļĨāļ°āđāļ—āđ‡āļšāđ€āļĨāđ‡āļ•
āļ•āļīāļ”āļ•āļąāđ‰āļ‡āđāļ­āļ› Google Play Books āļŠāļģāļŦāļĢāļąāļš Android āđāļĨāļ° iPad/iPhone āđāļ­āļ›āļˆāļ°āļ‹āļīāļ‡āļ„āđŒāđ‚āļ”āļĒāļ­āļąāļ•āđ‚āļ™āļĄāļąāļ•āļīāļāļąāļšāļšāļąāļāļŠāļĩāļ‚āļ­āļ‡āļ„āļļāļ“ āđāļĨāļ°āļŠāđˆāļ§āļĒāđƒāļŦāđ‰āļ„āļļāļ“āļ­āđˆāļēāļ™āđāļšāļšāļ­āļ­āļ™āđ„āļĨāļ™āđŒāļŦāļĢāļ·āļ­āļ­āļ­āļŸāđ„āļĨāļ™āđŒāđ„āļ”āđ‰āļ—āļļāļāļ—āļĩāđˆ
āđāļĨāđ‡āļ›āļ—āđ‡āļ­āļ›āđāļĨāļ°āļ„āļ­āļĄāļžāļīāļ§āđ€āļ•āļ­āļĢāđŒ
āļ„āļļāļ“āļŸāļąāļ‡āļŦāļ™āļąāļ‡āļŠāļ·āļ­āđ€āļŠāļĩāļĒāļ‡āļ—āļĩāđˆāļ‹āļ·āđ‰āļ­āļˆāļēāļ Google Play āđ‚āļ”āļĒāđƒāļŠāđ‰āđ€āļ§āđ‡āļšāđ€āļšāļĢāļēāļ§āđŒāđ€āļ‹āļ­āļĢāđŒāđƒāļ™āļ„āļ­āļĄāļžāļīāļ§āđ€āļ•āļ­āļĢāđŒāđ„āļ”āđ‰
eReader āđāļĨāļ°āļ­āļļāļ›āļāļĢāļ“āđŒāļ­āļ·āđˆāļ™āđ†
āļŦāļēāļāļ•āđ‰āļ­āļ‡āļāļēāļĢāļ­āđˆāļēāļ™āļšāļ™āļ­āļļāļ›āļāļĢāļ“āđŒ e-ink āđ€āļŠāđˆāļ™ Kobo eReader āļ„āļļāļ“āļˆāļ°āļ•āđ‰āļ­āļ‡āļ”āļēāļ§āļ™āđŒāđ‚āļŦāļĨāļ”āđāļĨāļ°āđ‚āļ­āļ™āđ„āļŸāļĨāđŒāđ„āļ›āļĒāļąāļ‡āļ­āļļāļ›āļāļĢāļ“āđŒāļ‚āļ­āļ‡āļ„āļļāļ“ āđ‚āļ›āļĢāļ”āļ—āļģāļ•āļēāļĄāļ§āļīāļ˜āļĩāļāļēāļĢāļ­āļĒāđˆāļēāļ‡āļĨāļ°āđ€āļ­āļĩāļĒāļ”āđƒāļ™āļĻāļđāļ™āļĒāđŒāļŠāđˆāļ§āļĒāđ€āļŦāļĨāļ·āļ­āđ€āļžāļ·āđˆāļ­āđ‚āļ­āļ™āđ„āļŸāļĨāđŒāđ„āļ›āļĒāļąāļ‡ eReader āļ—āļĩāđˆāļĢāļ­āļ‡āļĢāļąāļš

āļ­āđˆāļēāļ™āļ‹āļĩāļĢāļĩāļŠāđŒāļ™āļĩāđ‰āļ•āđˆāļ­

āļĢāļēāļĒāļāļēāļĢāļ­āļ·āđˆāļ™āđ† āļ—āļĩāđˆāđ€āļ‚āļĩāļĒāļ™āđ‚āļ”āļĒ Jack Cuzick

eBook āļ—āļĩāđˆāļ„āļĨāđ‰āļēāļĒāļāļąāļ™